BRCA1 and breast cancer: This is in contrast with the 70% of breast cancers in BRCA1 carriers which are triple-negative (1) and is therefore in keeping with the hypothesis that a reduction in circulating oestrogens/progesterones following RRSO would most likely reduce the risk of hormone-sensitive tumours.